LYT-200

N/A

Report date: 2026/03/04 20:01:44

Base Information

Drug NameLYT-200
Drug Alias NameLYT-200
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsAnti-Galactoside-binding lectin Galectin 9
TargetsGalactoside-binding lectin Galectin 9
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesNeoplasm Metastasis +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPuretech Health
China Registration ClassN/A

Develop Information

Active CompaniesPuretech Health
Inactive CompaniesN/A
Active IndicationsSolid tumoursMyelodysplastic SyndromesNeoplasm Metastasis +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A